AbbVie (ABBV) After 152% Run: Is the Stock Still Cheap?

AbbVie (ABBV) stock has delivered a strong 151.6% return over the past five years, putting long-term holders in a strong position. However, this rally raises questions about the current valuation and whether there is still an attractive entry point.

Valuation Divergence

Analysis of AbbVie's valuation reveals a clear split between two methodologies:

• Discounted Cash Flow (DCF) Model: Estimates the intrinsic value below the current price, suggesting a significant discount.
• Earnings Multiples: Indicate that the stock trades on the rich side relative to its earnings.

This divergence makes the investment decision more complex, depending on which methodology an investor favors.

Analyst Rationale

Analysts relying on DCF believe the stock is still undervalued, especially given growth expectations for AbbVie's new immunology and oncology products. Others argue that high earnings multiples already price in these expectations, limiting further upside.

Context

Despite strong performance, future returns will be more sensitive to the price paid today. New investors may face lower returns if the stock continues trading at current levels.

Conclusion

There is no consensus on AbbVie's valuation currently. Investors need to weigh the positive DCF signals against the caution from earnings multiples, while considering the company's product growth prospects.